MS disease progression study
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial is studying how multiple sclerosis (MS) progresses over time. It may help researchers understand the disease better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with multiple sclerosis (MS).
- You must be able to read and write.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study measures specific proteins in your blood that may help doctors understand how progressive multiple sclerosis advances. By tracking these markers over time, researchers hope to better predict disease progression and improve treatment decisions.
This study looks at why some people with relapsing-remitting multiple sclerosis (RRMS) get worse even when they don't have relapses. It uses eye scans and other tests to find early signs of progression, which could help tailor treatments.
This study follows people with multiple sclerosis to learn more about the disease and how it affects overall health. Researchers will collect information about your symptoms, treatments, and health outcomes over time to better understand MS and improve care.
This trial is looking at how people with multiple sclerosis experience clinical study enrollment and participation. It may help improve how future MS trials work and are explained, especially for different types of participants.
This study creates a registry for people with multiple sclerosis (MS) to track their health over time. The information gathered may help researchers better understand MS and improve care.
This study is looking for people with MS who are already on a monoclonal antibody therapy. It aims to measure subtle signs of disease progression using advanced tests, even if you feel stable.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.